CA1337115C - Vaccination against rabies-related diseases - Google Patents
Vaccination against rabies-related diseasesInfo
- Publication number
- CA1337115C CA1337115C CA000573293A CA573293A CA1337115C CA 1337115 C CA1337115 C CA 1337115C CA 000573293 A CA000573293 A CA 000573293A CA 573293 A CA573293 A CA 573293A CA 1337115 C CA1337115 C CA 1337115C
- Authority
- CA
- Canada
- Prior art keywords
- rabies
- virus
- protein
- cvs
- cfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010037742 Rabies Diseases 0.000 title claims abstract description 86
- 238000002255 vaccination Methods 0.000 title description 5
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 241000700605 Viruses Species 0.000 claims abstract description 84
- 230000001681 protective effect Effects 0.000 claims abstract description 23
- 230000036039 immunity Effects 0.000 claims abstract description 19
- 108090000288 Glycoproteins Proteins 0.000 claims description 18
- 102000003886 Glycoproteins Human genes 0.000 claims description 18
- 102000011931 Nucleoproteins Human genes 0.000 claims description 18
- 108010061100 Nucleoproteins Proteins 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000037452 priming Effects 0.000 claims description 13
- 230000001939 inductive effect Effects 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 32
- 229920001184 polypeptide Polymers 0.000 abstract description 22
- 238000000034 method Methods 0.000 abstract description 19
- 101710141454 Nucleoprotein Proteins 0.000 abstract description 18
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 17
- 208000015181 infectious disease Diseases 0.000 abstract description 12
- 230000000890 antigenic effect Effects 0.000 abstract description 3
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 3
- 229960005486 vaccine Drugs 0.000 description 34
- 239000002502 liposome Substances 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 241000711798 Rabies lyssavirus Species 0.000 description 24
- 102000004389 Ribonucleoproteins Human genes 0.000 description 20
- 108010081734 Ribonucleoproteins Proteins 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000002649 immunization Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 108091006027 G proteins Proteins 0.000 description 7
- 102000030782 GTP binding Human genes 0.000 description 7
- 108091000058 GTP-Binding Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 229940124861 Rabies virus vaccine Drugs 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000725171 Mokola lyssavirus Species 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101710084021 Large envelope protein Proteins 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000613130 Tima Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- QHGUCRYDKWKLMG-UHFFFAOYSA-N octopamine Chemical compound NCC(O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-UHFFFAOYSA-N 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 238000001503 one-tailed test Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7963987A | 1987-07-30 | 1987-07-30 | |
| US079,639 | 1987-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1337115C true CA1337115C (en) | 1995-09-26 |
Family
ID=22151834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000573293A Expired - Fee Related CA1337115C (en) | 1987-07-30 | 1988-07-28 | Vaccination against rabies-related diseases |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0326598A1 (de) |
| CA (1) | CA1337115C (de) |
| WO (1) | WO1989000861A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2645173B1 (fr) * | 1989-03-29 | 1994-06-17 | Pasteur Institut | Clonage et expression de genes codant pour des peptides et/ou des fragments de peptides du virus mokola, application a la preparation d'un v |
| AU2359195A (en) * | 1994-04-19 | 1995-11-10 | Thomas Jefferson University | Viral ribonucleocapsid as an immunological enhancer |
| CA2364150A1 (fr) * | 2001-12-07 | 2003-06-07 | Mireille Lafage | Polypeptides induisant l'apoptose, polynucleotides les codant et leurs applications therapeuthiques |
| CN103068985A (zh) | 2010-06-24 | 2013-04-24 | 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) | 抗狂犬病的广谱狂犬病病毒属病毒疫苗 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE72123T1 (de) * | 1985-04-19 | 1992-02-15 | Wistar Inst | Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. |
| EP0237686A1 (de) * | 1986-03-18 | 1987-09-23 | Institut Pasteur | Vom Tollwutvirus Genom abgeleitete DNS-Sequenzen |
-
1988
- 1988-07-28 CA CA000573293A patent/CA1337115C/en not_active Expired - Fee Related
- 1988-07-29 WO PCT/US1988/002529 patent/WO1989000861A1/en not_active Application Discontinuation
- 1988-07-29 EP EP88906760A patent/EP0326598A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0326598A1 (de) | 1989-08-09 |
| WO1989000861A1 (en) | 1989-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5837249A (en) | Method for generating an immunogenic T cell response protective against a virus | |
| Dietzschold et al. | Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. | |
| Perrin et al. | Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre-and post-exposure protection studies | |
| JPH03502687A (ja) | レスピラトリイ・シンシチアル・ウイルス：ワクチンおよび診断法 | |
| US5824309A (en) | Recombinant gas vesicles and uses thereof | |
| Audibert et al. | Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens | |
| CA1337115C (en) | Vaccination against rabies-related diseases | |
| JP4638880B2 (ja) | アルキルホスファチジルコリン配合ワクチン組成物 | |
| Liew | New aspects of vaccine development. | |
| WO1997020854A9 (en) | Recombinant gas vesicles and uses thereof | |
| US20230372466A1 (en) | Universal mammalian influenza vaccine | |
| TWI754817B (zh) | 以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產 | |
| EP1115382B1 (de) | Immunogene liposomzusammensetzungen | |
| AU608354B2 (en) | Vaccination against rabies-related viruses | |
| ES2379346T3 (es) | Composiciones de vacuna combinadas de ADN/proteína | |
| CA2090005C (en) | Cross-reactive influenza a immunization | |
| WO2024055273A1 (zh) | 一种狂犬病mRNA疫苗、其制备及应用 | |
| MXPA01010481A (es) | Acidos nucleicos y polipeptidos de lisavirus quimerico. | |
| KR100326938B1 (ko) | 지방산이 결합된 합성 펩타이드를 인지질 막에 재조합하여 제조한 조합물 및 그 제조방법 | |
| Liew | Biotechnology of vaccine development | |
| Levi | A synthetic approach to influenza vaccines | |
| Ben-Yedidia | A peptide-based vaccine against influenza | |
| WO1994022917A1 (en) | Cross-reactive influenza a immunization | |
| EP0547689A2 (de) | Zyklisches HIV PND und T-Zell stimulierendes Epitop enthaltende synthetische Peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |